By Dr Derek Jellinek
17 February 2023, 8:00 AM
Sonic Healthcare's (ASX:SHL) 1H underlying results were broadly inline, as slowing Covid-19 testing (-72%) impinged sales, compressed OPM and constrained OCF.
Read more...
By Dr Derek Jellinek
16 February 2023, 8:00 AM
Cochlear's (ASX:COH) 1H results were better than expected, underpinned by strong sales growth in both developed and emerging markets, but OPM declined on growth initiatives.
Read more...
By Dr Derek Jellinek
15 February 2023, 8:00 AM
CSL Limited's (ASX:CSL) 1H results were mixed, with underlying constant currency (cc) profit a little light (+9%), but on strong, in-line revenue growth (+25%).
Read more...
By Dr Derek Jellinek
30 January 2023, 8:00 AM
ResMed Inc's (ASX:RMD) 2Q was ahead of market expectations, with robust sales across all product lines, but with GM headwinds limiting robust operating leverage.
Read more...
By Scott Power
22 November 2022, 7:00 AM
At its AGM Nanosonics (ASX:NAN) provided a four-month trading update which showed a solid start to the year, with revenue up 42% and an increase in the installed base of 814 units.
Read more...
By Dr Derek Jellinek
14 November 2022, 8:00 AM
Ramsay Health Care's (ASX:RHC) 1Q trading update highlighted improving conditions across all markets, with revenue up 6.7%, as activity levels continue to improve in line with declining COVID cases, with positive momentum continuing into Oct and Nov.
Read more...
By Dr Derek Jellinek
18 October 2022, 7:00 AM
CSL Limited's (ASX:CSL) management remains “extremely confident” in its ability to drive long-term sustainable growth by better leveraging a much more diversified product portfolio and deeper pipeline.
Read more...
By Dr Derek Jellinek
14 September 2022, 7:00 AM
Deal talks have broken down between the KKR-led consortium and Ramsay Health Care's (ASX:RHC) Board, with both sides apparently digging-in their heels.
Read more...
By Dr Derek Jellinek
31 August 2022, 8:30 AM
Healius' (ASX:HLS) FY22 underlying results were broadly in line with expectations, with double-digit revenue growth and ongoing cost outs driving leverage and robust cash flow.
Read more...
By Dr Derek Jellinek
29 August 2022, 9:00 AM
Ramsay Health Care's (ASX:RHC) FY22 results continue to be materially impacted by COVID and higher costs, with margins contracting to multi-year lows and profit falling by double-digits.
Read more...